Royalty Pharma
RPRX
S$47.99
Share price
0.57%
Change (1 day)
24.60%
Change (1 year)
Categories
Royalty Pharma (RPRX) - Total debt
Total debt on the balance sheet as of March 2025 : S$9.80 Billion
According to Royalty Pharma's latest financial reports the company's total debt is S$9.80 Billion. A company’s total debt is the sum of all current and non-current debts.
Royalty Pharma - Total debt on balance sheet (from 2019 to 2025)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2024-12-31 | S$10.34 B | 27.7% |
| 2023-12-31 | S$8.10 B | -15.07% |
| 2022-12-31 | S$9.54 B | -0.55% |
| 2021-12-31 | S$9.59 B | 24.67% |
| 2020-12-31 | S$7.69 B | -8.5% |
| 2019-12-31 | S$8.41 B | -5.57% |
| 2018-12-31 | S$8.90 B |
Total debt for similar companies or competitors
| Company | Total debt/th> | differencediff. | Country |
|---|---|---|---|
 ANI Pharmaceuticals ANIP | S$0.80 B | -91.82% | 🇺🇸 USA |
 Abbott Laboratories ABT | S$17.04 B | 73.84% | 🇺🇸 USA |
 Eli Lilly LLY | S$49.59 B | 405.63% | 🇺🇸 USA |